FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Robert Q. Le(Center for Biologics Evaluation and Research), Richard Pazdur(United States Food and Drug Administration), Donna Przepiorka(The University of Texas MD Anderson Cancer Center), Weishi Yuan(Center for Drug Evaluation and Research), Ann T. Farrell(Center for Drug Evaluation and Research), Bahru Habtemariam(Center for Drug Evaluation and Research), Liang Li, Lei Nie(Center for Drug Evaluation and Research), Stacy S. Shord(Center for Drug Evaluation and Research)
The Oncologist
April 5, 2018
10.1634/theoncologist.2018-0028
Cited by 880

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Duration of Red-Cell Storage and Complications after Cardiac Surgery
|New England Journal of Medicine|2008|1.4k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k